Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Didox

Drug Profile

Didox

Alternative Names: N,3,4-trihydroxybenzamide (Didox); NSC 324360; VF 14

Latest Information Update: 26 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Molecules for Health
  • Class Antianaemics; Antineoplastics; Antipsoriatics; Antiretrovirals; Antivirals; Benzamides; Hydroxamic acids; Small molecules
  • Mechanism of Action Ribonucleoside diphosphate reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer
  • Preclinical Sickle cell anaemia
  • No development reported Cytomegalovirus infections; HIV infections; Psoriasis

Most Recent Events

  • 26 Sep 2022 Clinical development for Breast cancer is ongoing (Molecules for Health website, September 2022)
  • 10 Apr 2021 Pharmacodynamics data from preclinical studies in Breast cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
  • 28 Jul 2020 No recent reports of development identified for preclinical development in HIV-infections in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top